CD8A and neoplasm: The company’s TEGs technology enables the efficient expression of γδ TCR in αβ T cells, mediates tumor-specific proliferation of αβ T cells, and extensively infiltrates CD8+ effector T cells and CD4+ helper αβ T cells into tumors while not affecting normal organs.